Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022
Marie-Léa Gauci(Inserm), Célèste Lebbé(Inserm), Brigitte Dréno(Nantes Université), Astrid Blom(Université de Versailles Saint-Quentin-en-Yvelines), Nicole W.J. Kelleners-Smeets(Maastricht University Medical Centre), Véronique Bataille(King's College London), Ricardo Vieira(Hospitais da Universidade de Coimbra), Fábio Gomes(Cancer Research UK), D. Moreno‐Ramírez(Hospital Universitario Virgen Macarena), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Roland Kaufmann(Robert Koch Institute), Catherine Harwood(Queen Mary University of London), Axel Hauschild(University Hospital Schleswig-Holstein), Josep Malvehy(Universitat de Barcelona), Cynthia Aristei(University of Perugia), Christoph Höeller(Medical University of Vienna), Maria Concetta Fargnoli(University of L'Aquila), Aimilios Lallas(Aristotle University of Thessaloniki), Jürgen C. Becker(Düsseldorf University Hospital), Paul Lorigan(Manchester Academic Health Science Centre), V. del Mármol(Université Libre de Bruxelles), Alexander C. J. van Akkooi(The University of Sydney), Iris Zalaudek(Azienda Sanitaria Universitaria Integrata di Trieste), Ana‐Maria Forsea(Carol Davila University of Medicine and Pharmacy), Alexander J. Stratigos(National and Kapodistrian University of Athens), Ketty Peris(Università Cattolica del Sacro Cuore), Giovanni Pellacani(Sapienza University of Rome), Jean-Jacques Grob(Aix-Marseille Université), Claus Garbe(University of Tübingen)
Cited by 173
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k